Copyright 1978-2011 Lexicomp, Inc. All rights reserved.
(For additional information see “Acetohydroxamic acid: Patient drug information”)
Dosing: AdultSusceptible infections: Oral: 250 mg 3-4 times/day for a total daily dose of 10-15 mg/kg/day
Dosing: PediatricSusceptible infections: Oral: Initial: 10 mg/kg/day
Dosing: GeriatricRefer to adult dosing.
Dosing: Renal ImpairmentNot recommended for use in significant renal impairment (Srcr >2.5 mg/dL).
Dosage Forms: U.S.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Lithostat®: 250 mg
Generic Equivalent Available: U.S.No
AdministrationShould be administered on an empty stomach, 1 hour before or 2 hours after meals.
UseAdjunctive therapy in chronic urea-splitting urinary infection
Medication Safety Issues
Lithostat® may be confused with Lithobid®
Adverse Reactions Significant
Frequency not defined.
Cardiovascular: Deep vein thrombosis (rare), embolism, palpitation, phlebitis
Central nervous system: Anorexia, anxiety, depression, headache, malaise, nervousness, tremor
Dermatologic: Flushing (with ethanol consumption), rash (nonpruritic, macular)
Gastrointestinal: Nausea, vomiting
Hematologic: Hemolytic anemia (15% with laboratory evidence; ~3% severe requiring discontinuation; may be accompanied by GI symptoms or systemic complaints of malaise and/or fatigue); hyperbilirubinemia
Respiratory: Pulmonary embolism (rare)
ContraindicationsHypersensitivity to acetohydroxamic acid or any component of the formulation; pregnancy
Warnings/Precautions Concerns related to adverse effects:
• Bone marrow suppression: May suppress bone marrow function; use with caution in patients with prior bone marrow depression. Close monitoring of hematologic function is recommended.
• Hemolytic anemia: Has been associated with hemolytic anemia (Coombs’ negative), which may be associated with gastrointestinal distress and systemic symptoms; use with caution in patients with anemia. Monitor hematologic parameters during extended therapy.
• Hepatotoxicity: May cause hepatic injury; close monitoring of hepatic function is recommended.
• Psychiatric disorders: Use with caution in patients with pre-existing psychiatric disorders; may be associated with nervousness, anxiety, and/or depression.
(For additional information: Launch Lexi-Interact™ Drug Interactions Program )
There are no known significant interactions.
Ethanol: Avoid ethanol (may increase incidence of rash and/or flushing).
Food: May decrease absorption of acetohydroxamic acid.
Pregnancy Risk FactorX (show table)
LactationExcretion in breast milk unknown/not recommended
Dietary ConsiderationsShould be taken on an empty stomach, 1 hour before or 2 hours after meals.
Pricing: U.S. (www.drugstore.com)Tablets
250 mg (100): $169.98
Monitoring ParametersIn patients receiving therapy >2 weeks, monitor CBC with reticulocytes at 3-month intervals during the duration of treatment.
International Brand Names
- Uronefrex (BE, ES, FR, LU)
Mechanism of ActionAcetohydroxamic acid inhibits bacterial urease enzymes, decreasing the formation of ammonia in the urine by urea-splitting organisms. A reduction in urinary ammonia may increase the antibacterial activity of some antibiotic agents.